The study conducted by Nakanishi et al. (2020) found that RIV protected against cardiac dysfunction by inhibiting PAR-1, PAR-2 and proinflammatory cytokines, with effects observed after seven days in MI model mice. The gene discussed is F2RL1; the disease is myocardial infarction.